When Apellis Pharmaceuticals (APLS) secured FDA approval for EMPAVELI in C3 glomerulopathy and IC-MPGN last summer, the stock was trading near $28. Today it sits at $19.96, down 31% over the past year ...
15hOpinion
FDA experiments with America’s children
The U.S. Food and Drug Administration may soon convert an entire generation of U.S. children, especially children in foster ...
The Food and Drug Administration commissioner's effort to drastically shorten the review of drugs favored by President Donald ...
Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...
Questions remain among top Food and Drug Administration officials over who has the appropriate legal authority to sign off on ...
This is eight fewer than the FDA, which approved 46 novel drugs in 2025 – sneaking in two regulatory decisions during the ...
A rare but severe stem cell transplant complication that often becomes fatal now has its first FDA-approved treatment, a therapy developed by biotechnology company Omeros. The Christmas Eve regulatory ...
The next transformative phase of weight-loss medication is upon us, with the US Food and Drug Administration (FDA) approving Novo Nordisk's highly anticipated oral GLP-1 drug – with a starting dose ...
CAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients ...
The weight-loss drug market just got more crowded — and a lot less painful. The FDA on Monday approved a daily pill version of Novo Nordisk’s Wegovy, making it the first oral GLP-1 obesity treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback